SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gains on collaborating with American Academy of Ophthalmology

11 Jul 2017 Evaluate

Lupin is currently trading at Rs. 1153.00, up by 3.25 points or 0.28% from its previous closing of Rs. 1149.75 on the BSE.

The scrip opened at Rs. 1161.50 and has touched a high and low of Rs. 1166.85 and Rs. 1149.55 respectively. So far 61189 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1036.80 on 05-Jul-2017.

Last one week high and low of the scrip stood at Rs. 1166.85 and Rs. 1036.80 respectively. The current market cap of the company is Rs. 52314.15 crore.

The promoters holding in the company stood at 46.70%, while institutions and non-institutions held 40.66% and 12.63% respectively.

Lupin has entered into collaboration with the American Academy of Ophthalmology that would seek to expand and enhance continuing ophthalmic education in India. The effort is expected to reach 3,000 ophthalmologists in the country.

The collaboration will provide ophthalmologists access to several clinical education tools including the Academy’s flagship clinical education resource, the Ophthalmic News and Education Network. The World’s largest online compendium of ophthalmic knowledge, the ONE Network is accessed by approximately 130,000 users every month.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2344.95 -32.95 (-1.39%)
11-May-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1839.85
Dr. Reddys Lab 1293.00
Cipla 1340.75
Zydus Lifesciences 940.00
Lupin 2344.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×